Patent intelligence · US
US 11622991
Protocol for treatment of lupus nephritis
Protocol for treatment of lupus nephritis
Patent details — US 11622991
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 11, 2023
- Expiration
- Apr 6, 2043
- Applicant
- AURINIA PHARMACEUTICALS INC.
- Claims
- 27
- CPC classes
- A61K, A61K31/343, A61K31/5377, A61K31/573
Quick answer
US 11622991 (Protocol for treatment of lupus nephritis) is held by AURINIA PHARMACEUTICALS INC.. Status: granted. Granted Apr 11, 2023. Expires Apr 6, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AURINIA PHARMACEUTICALS INC.
- Grant date
- Expiration
- Claims
- 27
- CPC classes
- A61K, A61K31/343, A61K31/5377, A61K31/573, A61K38/13, A61P
More from AURINIA PHARMACEUTICALS INC.
Related pharmaceutical patents in our USPTO index.
-
US 10973871
Ophthalmic compositions
granted -
US 10472394
Cyclosporine analogue mixtures and their use as immunomodulating agents
granted -
US 10286036
Protocol for treatment of lupus nephritis
granted -
US 10265375
Ophthalmic compositions
granted -
US 9765119
Cyclosporine analogue mixtures and their use as immunomodulating agents
granted -
US 9017725
Topical drug delivery systems for ophthalmic use
granted
Frequently asked questions
What is US patent 11622991?
US 11622991 (Protocol for treatment of lupus nephritis) is held by AURINIA PHARMACEUTICALS INC.. Status: granted. Granted Apr 11, 2023. Expires Apr 6, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11622991?
AURINIA PHARMACEUTICALS INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 11622991 expire?
Our index shows an expiration date of Apr 6, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.